Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Cardiovascular Drugs
Published in: American Journal of Cardiovascular Drugs 1/2001

01-01-2001 | Therapy in Practice

Current Management of Acute Symptomatic Deep Vein Thrombosis

Author: Dr John A. Heit

Published in: American Journal of Cardiovascular Drugs | Issue 1/2001

Login to get access

Abstract

Venous thromboembolism is a common and potentially fatal disease. If properly used, anticoagulation therapy is effective in preventing recurrence of venous thromboembolism and in improving survival. Symptomatic patients with an objective diagnosis of acute deep vein thrombosis (DVT) or pulmonary embolism (PE) should receive immediate systemic heparin anticoagulation at dosages sufficient to rapidly prolong the activated partial thromboplastin time into the laboratory-specific therapeutic range; this range corresponds to a plasma heparin concentration of 0.2 to 0.4 IU/ml (as measured by protamine sulfate titration), or 0.3 to 0.7 anti-Xa IU/ml. An oral vitamin K antagonist (e.g. warfarin) should be started within 24 hours after starting heparin; the starting dose should be the estimated patient-specific daily dose with no loading dose. Heparin and warfarin anticoagulation should be overlapped for at least 4 to 5 days and until the international normalized ratio (INR) is within the therapeutic range (2.0 to 3.0) on 2 measurements made at least 24 hours apart.
The duration of warfarin anticoagulation should be individualized based on the respective risks of venous thromboembolism recurrence and anticoagulant-related bleeding. In general, warfarin should be continued for at least 3 months, and longer for patients with recurrent or idiopathic venous thromboembolism, malignant neoplasm, neurologic disease with extremity paresis, obesity, or laboratory evidence of a lupus anticoagulant/anticardiolipin antibody, homozygous carrier or combined heterozygous carrier for the factor V R506Q (Leiden) and prothrombin G20210A mutations, and possibly deficiency of either antithrombin, protein C, or protein S.
Low molecular weight heparin (LMWH) is effective and well tolerated as acute therapy for patients with DVT or stable PE, and does not require laboratory monitoring or dose adjustment. Outpatient LMWH therapy is also well tolerated and cost effective for most patients with DVT, and possibly for selected patients with PE.
Literature
1.
Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585–93PubMedCrossRef
2.
Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism. Arch Intern Med 1999; 159: 445–53PubMedCrossRef
3.
Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761–8PubMedCrossRef
4.
Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998 Nov; 114 (5 Suppl.): 561S–78SPubMedCrossRef
5.
Brandjes CPM, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared to acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485–9PubMedCrossRef
6.
Hellemans J, Vorlat M, Verstraete M. Survival time of prothrombin and factors VII, IX, and X after completely synthesis blocking doses of coumarin derivatives. Br J Haematol 1963; 9: 506–12PubMedCrossRef
7.
Zivelin A, Rao LVM, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest 1993; 92: 2131–40PubMedCrossRef
8.
Heit JA, Stewart ML, Owen WG. The role of plasma prothrombin activity in the acute thrombotic response to severe arterial injury. Thromb Haemost 1995; 73: 1341
9.
Hull RD, Raskob GE, Brant RF, et al. Relationship between time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157: 2562–8PubMedCrossRef
10.
Hull RD, Rascob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986; 315: 1109–14PubMedCrossRef
11.
Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333–7PubMedCrossRef
12.
Raschke RA, Reilly BM, Guidry JR, et al. The weight-based dosing nomogram compared with a standard care nomogram. Ann Intern Med 1993; 119: 874–81PubMed
13.
Anand S, Ginsberg J, Kearon C, et al. The relationship between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996; 156: 1677–81PubMedCrossRef
14.
Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range of heparin therapy. Ann Intern Med 1993; 119: 104–9PubMed
15.
Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (5 Suppl.): 489S–510SPubMedCrossRef
16.
Young E, Prins M, Levine M, et al. Heparin binding to plasma proteins, and important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639–43PubMed
17.
Kraaigenhagen RA, in’t Anker PS, Koopman MMW, et al. High plasma concentration of Factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5–9
18.
Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343:457–62PubMedCrossRef
19.
Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606–11PubMed
20.
Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49–56PubMedCrossRef
21.
Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1–17PubMed
22.
23.
Young E, Wells PS, Holloway S, et al. Ex-vivo and in-vivo evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300–4PubMed
24.
Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975–83PubMedCrossRef
25.
Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441–5PubMedCrossRef
26.
Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin. N Engl J Med 1995; 332: 1330–5PubMedCrossRef
27.
Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677–81PubMedCrossRef
28.
Koopman MMW, Prandoni P, Piovelli F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. N Engl J Med 1996; 334: 682–7PubMedCrossRef
29.
Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. N Engl J Med 1997; 337: 663–9PubMedCrossRef
30.
The Columbus Investigators. Low-molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657–62CrossRef
31.
Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998; 158: 1809–12PubMedCrossRef
32.
Brandjes DPM, Büller HR, Heijboer H, et al. Randomized trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759–62PubMedCrossRef
33.
Lindmarker P, Holmstrom H. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis: a feasibility and health economic study in an outpatient setting. J Intern Med 1996; 240: 395–401PubMedCrossRef
34.
Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76: 195–9PubMed
35.
van der Heijden JF, Prins MH, Büller, HR. For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? Thromb Res 2000; 100: V121–30PubMedCrossRef
36.
Gould MK, Dembitzer AD, Sanders G, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 1999; 130: 789–99PubMed
37.
Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260–4PubMedCrossRef
38.
White RH, Zhou H, Romano PS. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med 1998; 158: 1005–10PubMedCrossRef
39.
Godal HC, Madsen K, Nissen-Meyer R. Thrombo-embolism in patients with total proconvertin (factor VII) deficiency: a report of two cases. Acta Med Scand 1962; 171: 325–7PubMedCrossRef
40.
Greshwin ME, Gude JK. Deep vein thrombosis and pulmonary embolism in congenital factor VII deficiency. N Engl J Med 1973; 288: 141–2CrossRef
41.
Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126: 133–6PubMed
42.
Schulman S, Rhedin A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661–5PubMedCrossRef
43.
Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulation therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393–8PubMedCrossRef
44.
Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901–7PubMedCrossRef
45.
Schulman S, Svenungsson E, Granqvist S, et al. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332–8PubMedCrossRef
46.
De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 801–6PubMedCrossRef
47.
De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 1996; 87 (9): 3531–44PubMed
48.
Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 1. Thromb Haemost 1996; 76 (5): 651–62PubMed
49.
Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 2. Thromb Haemost 1996; 76 (6): 824–34PubMed
50.
Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517–32PubMed
Metadata
Title
Current Management of Acute Symptomatic Deep Vein Thrombosis
Author
Dr John A. Heit
Publication date
01-01-2001
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs / Issue 1/2001
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.2165/00129784-200101010-00005

Other articles of this Issue 1/2001

American Journal of Cardiovascular Drugs 1/2001 Go to the issue

Therapy in Practice

Medical Management of Chronic Heart Failure in Children

Review Article

Role of Metabolically Active Drugs in the Management of Ischemic Heart Disease

OriginalPaper

From the World Literature

Leading Article

β-Blockade in Heart Failure

Drug Evaluation

Tenecteplase

Leading Article

Clinical Potential of Photodynamic Therapy in Cardiovascular Disorders